Cell therapy for solid tumours
The first CAR-T approved for a solid tumour (CLDN18.2-positive stomach and gastro-oesophageal cancer), approved in China in June 2026.
Read more →Treatments we can arrange
These are areas where China offers something hard to get in the West, or the same care much sooner or at lower cost. Every case starts with an assessment; suitability is decided by the treating doctors.
Implanted brain–computer interface
An implanted device to restore hand function after cervical spinal cord injury, approved in China in March 2026.
Read more →Carbon-ion radiotherapy
Heavy-ion beams for selected pancreatic, head-and-neck, skull-base, prostate and recurrent tumours.
Read more →Boron neutron capture therapy (BNCT)
A targeted radiation technique for selected recurrent head-and-neck cancers.
Read more →New cancer antibodies and ADCs
Medicines approved in China that are not yet approved in Canada, the US or the EU, for selected lung, cervical, gastric and breast cancers.
Read more →Gene therapy for blood disorders
One-time gene therapy for haemophilia B, and gene therapy programmes for thalassaemia, at a fraction of Western list prices.
Read more →CAR-T and TIL cell therapy
Cell therapies for lymphoma, leukaemia, myeloma and melanoma, often available within weeks.
Read more →Focused ultrasound (HIFU)
Non-surgical treatment for uterine fibroids and adenomyosis, from the centres that developed the technique.
Read more →Interventional oncology
Liver-directed chemotherapy (HAIC), irreversible electroporation and ablation for tumours that cannot be operated on.
Read more →Second opinions
Complex or undiagnosed conditions reviewed by leading teams in neurology, cardiology, hand surgery and rare disease.
Read more →Why an introduction matters
Many of China’s leading specialists work in busy public hospitals without international patient offices. They rarely answer enquiries from abroad directly, and a file sent without an introduction often goes unread. Cases usually reach them through people they already know and trust. Our team on the ground makes that introduction, presents your case properly in Chinese, and follows up until you have an answer.
Hospital names, doctors and contacts are shared with clients after the case assessment.
Some programmes, especially stem-cell and other cell treatments, are experimental. We introduce them only if you ask and your own specialist agrees, and we never describe them as cures.
Sources: OncLive, 22 Jun 2026 · MassDevice, Mar 2026